Smith & Nephew SNATS (NYSE:SNN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Smith & Nephew SNATS (NYSE:SNN) from a buy rating to a strong-buy rating in a report released on Sunday.

A number of other research firms also recently issued reports on SNN. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Canaccord Genuity Group boosted their target price on Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada downgraded Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Smith & Nephew SNATS currently has a consensus rating of “Hold” and a consensus price target of $36.25.

Smith & Nephew SNATS Stock Up 0.7%

SNN opened at $31.81 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 12 month low of $23.91 and a 12 month high of $38.79. The firm’s fifty day simple moving average is $34.26 and its 200 day simple moving average is $34.30.

Smith & Nephew SNATS (NYSE:SNN) last released its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The firm had revenue of $1.60 billion for the quarter. On average, research analysts expect that Smith & Nephew SNATS will post 1.69 earnings per share for the current fiscal year.

Smith & Nephew SNATS Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be given a dividend of $0.482 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a yield of 304.0%.

Hedge Funds Weigh In On Smith & Nephew SNATS

Hedge funds have recently modified their holdings of the stock. Garner Asset Management Corp bought a new stake in Smith & Nephew SNATS during the fourth quarter worth about $27,000. Arax Advisory Partners grew its stake in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 569 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Smith & Nephew SNATS during the 4th quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Smith & Nephew SNATS during the 3rd quarter worth approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Smith & Nephew SNATS during the 4th quarter worth approximately $43,000. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.